Wei Teng1, Tzu-Ching Chang2, Chien-Hao Huang2, Wen-Juei Jeng2, Wei-Ting Chen2, Chang-Wen Huang2, Yu-Pin Ho1, Chun-Yen Lin2,3, I-Shyan Sheen2,3
1Department of Gastroenterology and Hepatology, Linkou Medical Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan
2Division of Hepatology, Department of Gastroenterology and Hepatology, Linkou Medical Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan
3School of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan
Tóm tắt
SummaryBackground and aimsRapid null response (rNR), defined as less than one log decline of Hepatitis C virus (HCV‐RNA) at Week 4 of treatment with pegylated interferon‐α and ribavirin (PegIFN/RBV), is highly correlated with treatment failure in patients with chronic hepatitis C (CHC), genotype‐1 (GT‐1). In this study, we investigate the possible predictors of rNR.MethodsWe retrospectively analyzed a cohort of 199 GT‐1 CHC naive patients who had been treated with a dual therapy of PegIFN/RBV. Clinical parameters and genotypes of rs12979860, the single nucleotide polymorphisms (SNPs) of interleukin‐28B (IL28B) were analyzed for their relationship with rNR.ResultsOf the patients analyzed, 41.7% did not exhibit a rapid virological response (RVR). Only 13.1% of patients who experienced a rNR showed an RVR. The treatment failure rate was 36.2%. High baseline viral load (OR: 5.74; p = 0.028), nonrapid virological response (non‐RVR; OR: 4.32; p = 0.004) and rNR (OR: 51.82; p < 0.001) were the predictors of treatment failure. In addition, both the non‐CC allele of rs12979860 (OR: 13.8; p < 0.001) and the Hb (hemoglobin) decline to < 3 g/dL within 4 weeks of treatment (no early anemia; OR: 4.6; p = 0.024) were predictors of rNR.ConclusionsrNR predicted treatment failure early in GT‐1 CHC patients treated with PegIFN/RBV. Non‐CC genotype of rs12979860 and no early anemia were significant predictors of rNR.
